Literature DB >> 11368882

Invariant chain expression in gastric cancer.

S Ishigami1, S Natsugoe, K Tokuda, A Nakajo, H Iwashige, K Aridome, S Hokita, T Aikou.   

Abstract

Invariant chain (Ii) is a chaperone molecule that inhibits the binding of endogenous antigens to HLA class II. The tumor cell with overexpressed Ii chain is thought to escape attacking cytotoxic lymphocytes by suppressing the host immune. However, the relationship between Ii expression by the tumor and clinicopathological factors in gastric cancer remains unclear. We studied 126 patients with gastric cancer who had undergone curative gastrectomy at Kagoshima University Hospital between 1988 and 1997. In order to detect Ii and HLA-DR expression by tumor cells, immunohistochemical staining with anti-CD74 and anti-HLA-DR antibodies were performed by avidin-biotin peroxidase complex method. The 126 patients studied were divided into two groups based on Ii expression. Ii and HLA-DR were expressed both on the surface and in the cytoplasm of tumor cells and tumor infiltrating lymphocytes. A total of 48 patients were identified as Ii positive, while the remaining 78 patients were Ii negative. Ii expression negatively correlated with the depth of invasion of the tumor as well as the patients' clinical stage. Ii expression was negatively correlated with HLA-DR expression. Patients with Ii negative expression had significantly better surgical outcomes than those with Ii positive expression (P<0.05). Ii expression in gastric cancer affected surgical outcome and Ii expression was negatively correlated with depth of invasion and HLA-DR expression. Ii expression in gastric cancer may be a prognostic factor related to suppressive effects on host immune responses to tumor cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11368882     DOI: 10.1016/s0304-3835(01)00503-1

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  19 in total

1.  The cytokine midkine and its receptor RPTPζ regulate B cell survival in a pathway induced by CD74.

Authors:  Sivan Cohen; Or-yam Shoshana; Einat Zelman-Toister; Nitsan Maharshak; Inbal Binsky-Ehrenreich; Maya Gordin; Inbal Hazan-Halevy; Yair Herishanu; Lev Shvidel; Michal Haran; Lin Leng; Richard Bucala; Sheila Harroch; Idit Shachar
Journal:  J Immunol       Date:  2011-12-02       Impact factor: 5.422

2.  Identification of biomarkers of human pancreatic adenocarcinomas by expression profiling and validation with gene expression analysis in endoscopic ultrasound-guided fine needle aspiration samples.

Authors:  Henrik Laurell; Michele Bouisson; Philippe Berthelemy; Philippe Rochaix; Sebastien Dejean; Philippe Besse; Christiane Susini; Lucien Pradayrol; Nicole Vaysse; Louis Buscail
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

3.  Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance.

Authors:  Gaspar J Kitange; Brett L Carlson; Mark A Schroeder; Paul A Decker; Bruce W Morlan; Wenting Wu; Karla V Ballman; Caterina Giannini; Jann N Sarkaria
Journal:  J Neurooncol       Date:  2010-05-05       Impact factor: 4.130

4.  CD74 and macrophage migration inhibitory factor as therapeutic targets in gastric cancer.

Authors:  Ying-Xia Zheng; Ming Yang; Ting-Ting Rong; Xiang-Liang Yuan; Yan-Hui Ma; Zhi-Hao Wang; Li-Song Shen; Long Cui
Journal:  World J Gastroenterol       Date:  2012-05-14       Impact factor: 5.742

5.  CD74 is a survival receptor on colon epithelial cells.

Authors:  Nitsan Maharshak; Sivan Cohen; Frida Lantner; Gili Hart; Lin Leng; Richard Bucala; Idit Shachar
Journal:  World J Gastroenterol       Date:  2010-07-14       Impact factor: 5.742

Review 6.  Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.

Authors:  Cédric Rossi; Marie-Lorraine Chrétien; René-Olivier Casasnovas
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

7.  A retroviral mutagenesis screen identifies Cd74 as a common insertion site in murine B-lymphomas and reveals the existence of a novel IFNgamma-inducible Cd74 isoform.

Authors:  Magdalena Pyrz; Bruce Wang; Matthias Wabl; Finn Skou Pedersen
Journal:  Mol Cancer       Date:  2010-04-23       Impact factor: 27.401

8.  Target proteomic profiling of frozen pancreatic CD24+ adenocarcinoma tissues by immuno-laser capture microdissection and nano-LC-MS/MS.

Authors:  Jianhui Zhu; Song Nie; Jing Wu; David M Lubman
Journal:  J Proteome Res       Date:  2013-05-29       Impact factor: 4.466

Review 9.  CD74 in antigen presentation, inflammation, and cancers of the gastrointestinal tract.

Authors:  Ellen J Beswick; Victor E Reyes
Journal:  World J Gastroenterol       Date:  2009-06-21       Impact factor: 5.742

10.  Identification of potential therapeutic targets in human head & neck squamous cell carcinoma.

Authors:  Jing Han; Mitomu Kioi; Wei-Sing Chu; Jan L Kasperbauer; Scott E Strome; Raj K Puri
Journal:  Head Neck Oncol       Date:  2009-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.